poisar

Stocks · News reference

OKYO To Initiate Global Phase 3 NEPTUNE Trial In Neuropathic Eye Pain, Enrolling 111 Patients Across US And Europe In 2026 Following Positive FDA Feedback

Jul 20, 2026, 11:16 AMBenzinga Newsdesk

OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced

Read original sourceMore stocks news

Reference details

Connected markets

Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.

OKYO
Source
benzinga
Observed
Jul 20, 2026, 11:16 AM
Checked
Jul 20, 2026, 11:16 AM
Cadence
Captured once, then retained as an archive reference
Status
fresh

Keep reading